WIF1 and neoplasm: This might be attributed to factors such as tumor heterogeneity, interactions within TME (changes like immune infiltration within TME might affect WIF-1 expression), selective pressure induced by immunotherapy (ineffective immunotherapy might allow survival of treatment-resistant tumor cells, which might exhibit higher WIF-1 expression as a survival mechanism in PD patients), or the direct/indirect effects of immunotherapeutic drugs.